engin
vaccinebas
therapeut
infecti
diseas
highli
challeng
trial
formul
often
found
nonspecif
ineffect
thermal
hydrolyt
unstabl
andor
toxic
vaccin
greatli
improv
therapeut
landscap
treat
infecti
diseas
significantli
reduc
threat
therapeut
prevent
approach
furthermor
advent
recombin
technolog
greatli
facilit
growth
within
vaccin
realm
mitig
risk
virul
revers
despit
make
product
process
cumbersom
addit
seroconvers
also
enhanc
recombin
technolog
kinet
nonkinet
approach
discuss
herein
recombin
technolog
greatli
improv
amino
acidbas
vaccin
dnabas
vaccin
plateau
interest
reach
scientif
commun
regard
dna
vaccin
endeavor
decreas
interest
may
like
attribut
difficulti
improv
immunogen
properti
associ
dna
vaccin
although
research
demonstr
improv
optim
end
despit
improv
extent
knowledg
current
regulatori
bodyapprov
dna
vaccin
human
use
four
vaccin
approv
anim
use
articl
discuss
engin
dna
vaccin
infecti
diseas
discuss
advantag
disadvantag
emphasi
applic
dna
vaccin
review
paper
summar
state
engineeredrecombin
dna
vaccin
field
scope
entail
engin
dna
vaccin
infecti
diseas
endeavor
emphas
recent
advanc
recapitul
current
state
field
addit
discuss
dna
therapeut
alreadi
clinic
translat
review
also
examin
current
research
develop
challeng
thwart
progress
review
cover
recombin
dnabas
subunit
vaccin
intern
process
enhanc
immun
protect
via
adjuv
manufactur
engin
dna
safeti
stabil
deliveri
dna
vaccin
plasmid
control
gene
express
use
plasmid
engin
gene
circuit
overcom
immunogen
issu
commerci
success
hope
review
inspir
research
dna
vaccin
develop
infecti
diseas
caus
varieti
microogan
includ
bacteria
virus
often
lead
decreas
qualiti
life
increas
risk
mortal
million
peopl
die
due
human
immunodefici
viru
hiv
alon
infecti
diseas
burden
delin
use
disabilityadjust
life
year
dali
infecti
diseas
list
world
health
organ
number
top
contribut
issu
regard
infecti
diseaserel
dali
lower
respiratori
infecti
diseas
hivaid
tuberculosi
per
rank
respect
variou
therapeut
prevent
intervent
use
combat
infecti
diseas
vaccin
particular
play
critic
role
prevent
treat
even
erad
diseas
ie
smallpox
poliomyel
polio
anoth
deadli
infecti
diseas
mainli
affect
children
inactiv
polio
vaccin
oral
polio
vaccin
two
type
vaccin
help
reduc
polio
worldwid
popul
worldwid
live
poliofre
region
inactiv
polio
vaccin
immun
help
global
erad
wild
polioviru
type
serotyp
polio
vaccin
remain
effect
despit
evolut
viru
antigen
select
gener
antibodi
conserv
region
howev
pathogen
hypervari
vaccin
efficaci
may
limit
dna
vaccin
use
overcom
challeng
engin
dna
encod
specif
antigen
dna
recombinantbas
subunit
vaccin
known
enhanc
stabil
degre
transport
storag
comparison
tradit
proteinbas
vaccin
greater
control
risk
virul
revers
use
dna
vaccin
therefor
dna
vaccin
consid
aspect
safer
dna
vaccin
potenti
greater
util
immunocompromis
patient
howev
remain
issu
must
resolv
enabl
dna
vaccin
clinic
translat
human
use
main
remain
issu
lack
immunogen
associ
dna
vaccin
current
state
dna
vaccin
discuss
within
review
articl
specif
review
discuss
recombin
dna
subunit
vaccin
mechan
intern
process
enhanc
durat
protect
nonkinet
approach
manufactur
engin
dna
safeti
stabil
dna
vaccin
plasmid
deliveri
control
gene
express
plasmid
engin
gene
circuit
overcom
immunogen
issu
dna
vaccin
exampl
success
commerci
dna
vaccin
also
report
perspect
futur
direct
field
brief
overview
vaccin
classif
found
tabl
extens
review
written
contain
inform
regard
vaccin
classif
name
live
attenu
vaccin
polysaccharid
vaccin
inactiv
vaccin
dna
vaccin
fig
show
number
public
april
differ
type
vaccin
indic
popular
report
valu
base
pubm
result
use
endnot
project
valu
indic
asterisk
calcul
multipli
current
valu
ratio
number
total
month
within
timefram
interest
divid
number
month
date
dna
vaccin
particular
show
increas
number
pubm
result
compar
vaccin
type
howev
hype
dna
vaccin
dampen
therebi
reach
plateau
like
owe
difficulti
achiev
suffici
immunogen
level
protect
dna
vaccin
howev
engin
effect
zero
risk
virul
revers
recombin
dna
subunit
vaccin
replic
vector
typic
yeast
bacteria
transform
engin
dna
sequenc
transcript
translat
administ
patient
instanc
hepat
b
dna
vaccin
base
differ
domain
hepat
b
viru
surfac
antigen
hbsag
often
administ
adjuv
improv
immunogen
dna
vaccin
encod
antigen
mainli
elicit
humor
immun
respons
similar
natur
infect
hepat
b
dna
vaccin
often
administ
use
liposom
cation
carrier
tabl
gener
qualit
comparison
vaccin
classif
pleas
note
except
may
contradict
gener
qualit
comparison
detail
administr
rout
advantag
disadvantag
regard
product
immunogen
biosafeti
transportationstorag
exampl
commerci
dnaand
amino
acidbas
vaccin
vaccin
classif
tabul
denot
gener
pro
con
dna
protein
vaccin
share
major
part
product
process
vari
mechan
elicit
immun
system
first
step
consist
insert
gene
interest
goi
plasmid
vector
follow
transform
replic
bacteria
yeast
replic
recombin
protein
extract
purifi
prepar
vaccin
case
dna
vaccin
replic
vector
usual
disrupt
engin
dna
extract
purifi
produc
final
vaccin
administr
patient
recombin
protein
vaccin
intern
within
host
cell
process
antigen
peptid
elicit
cell
respons
dna
vaccin
must
achiev
intern
nucleu
use
host
molecular
machineri
promot
transient
express
goi
transcript
translat
goi
process
antigen
peptid
antigen
peptid
elicit
immun
respons
case
dna
vaccin
engin
dna
administ
patient
without
ie
gene
gun
carrier
gener
nonvir
gene
deliveri
result
transient
gene
express
tge
antigen
interest
dna
vaccin
introduc
late
wolff
et
al
intramuscularli
inject
plasmid
dna
pdna
mice
subsequ
jiao
et
al
propos
deliveri
dna
plasmid
nonhuman
primat
ulmer
et
al
describ
vaccin
influenza
use
pdna
mice
follow
section
provid
indepth
inform
dna
vaccin
manufactur
engin
dna
vaccin
safeti
stabil
dna
vaccin
kinet
control
dna
vaccin
releas
barrier
deliveri
pdna
vaccin
activ
nuclear
transport
nuclear
uptak
dna
control
gene
express
plasmid
engin
gene
circuit
techniqu
overcom
immunogen
issu
dna
vaccin
physic
method
dna
vaccin
deliveri
preclin
clinic
trial
pro
dna
vaccin
low
product
cost
compar
protein
vaccin
enhanc
stabil
transport
storag
administ
immunocompromis
patient
con
low
immunogen
may
requir
multipl
booster
dose
fig
delin
plasmid
amino
acidbas
vaccin
mechan
intern
process
vari
addit
antigen
present
respect
pleas
note
fig
certain
cellular
process
shown
gener
somat
cell
ie
plasmid
deliveri
process
antigen
present
cell
apc
ie
mhc
iiipeptid
display
exampl
translat
product
within
somat
cell
plasmid
could
transport
extracellularli
uptaken
apc
vaccin
process
three
main
pathway
direct
somat
cell
engulfmentapc
display
fig
thu
lead
mhc
iipeptid
display
phagocytosi
transfect
nonvir
transform
viral
cellcrossprim
fig
thu
lead
mhc
ipeptid
display
tolllik
receptor
tlr
activ
fig
vaccin
may
taken
intracellularli
endocytosi
within
apc
fig
interact
extracellularli
pathway
therebi
result
express
proinflammatori
cytokin
chemokin
interleukin
il
tnfa
fig
nonvir
gene
deliveri
system
use
deliv
dna
vaccin
proton
spong
effect
play
import
role
pdna
escap
endolysosom
degrad
pathway
fig
pdna
either
randomli
encapsul
nuclear
envelop
reform
postmitosi
activ
transport
nucleu
nuclear
local
signal
ie
dnatarget
sequenc
dna
vaccin
may
contain
unmethyl
cpg
sequenc
function
pathogenassoci
molecular
pattern
pamp
activ
endosom
eventu
releas
interferon
ifn
fig
enhanc
durat
immun
protect
nonkinet
approach
achiev
molecular
immunostimul
eg
nucleic
acid
polysaccharid
protein
polym
advanc
vaccin
particl
eg
nanoparticl
microparticl
viruslik
particl
tabl
biopolym
ie
polysaccharid
chitosan
wide
use
medic
applic
report
adjuv
action
specif
applic
exampl
polysaccharidebas
adjuv
also
improv
immunogen
vaccin
chitosan
known
mucoadhes
may
exhibit
import
role
mucos
immun
sawaengsak
et
al
extracellular
activ
result
express
proinflammatori
cytokin
chemokin
tnfa
proton
spong
effect
dna
vaccin
cpg
sequenc
activ
result
ifna
releas
cytosol
degrad
pathway
result
mhc
ii
antigen
present
cell
proteasom
degrad
pathway
eventu
mhc
antigen
present
cell
direct
somat
cell
engulfmentapc
display
entail
lead
mhc
iipeptid
display
step
phagocytosi
transfect
nonvir
transform
viral
cellcrossprim
entail
lead
mhc
display
step
tolllik
receptor
tlr
activ
entail
apc
antigenpres
cell
cc
chemokin
receptor
type
cpg
dna
dna
fragment
contain
cytosin
nucleotid
follow
guanin
nucleotid
er
endoplasm
reticulum
ifn
interferon
il
interleukin
mhc
major
histocompat
complex
tnf
tumor
necrosi
factor
tlr
tolllik
receptor
vlp
viruslik
particl
fig
dnaand
amino
acidbas
antigen
present
antibodymedi
cellmedi
respons
depend
context
antigen
present
apc
antigenpres
cell
ctl
cytotox
lymphocyt
ifn
interferon
ig
immunoglobulin
il
interleukin
mhc
major
histocompat
complex
tcr
cell
receptor
th
helper
cell
tnf
tumor
necrosi
factor
exampl
adjuv
report
nanoparticl
chitosan
combin
tripolyphosph
hemagglutinin
ha
induc
twofold
increas
number
splenocyt
secret
ifnc
mice
infect
influenza
viru
compar
nonadjuv
ha
vaccin
gordon
et
al
report
inulinbas
adjuv
advax
elicit
effici
immun
respons
hepat
b
phase
least
fourfold
increas
seroprotect
tcell
respons
observ
subject
immun
advax
compar
hbsag
alon
howev
biopolym
difficulti
control
drug
releas
owe
solubl
water
exampl
report
compar
pectin
content
demonstr
higher
pectin
content
result
increas
eros
thu
lead
faster
drug
releas
basi
type
applic
concept
advantag
disadvantag
depend
length
scale
drug
releas
desir
report
pectinamylos
formul
releas
drug
within
h
timefram
gastrointestin
context
rel
nontox
degrad
ie
hydrolysi
ester
amidolysi
amid
polym
poli
anhydrid
pa
polynisopropyl
acrylamid
pnipaam
plga
found
applic
vaccin
tamayo
et
al
report
recognit
pa
nanoparticl
therebi
elicit
cell
respons
polar
inform
regard
polar
refer
fig
mice
wafa
et
al
show
polymer
structur
affect
intens
cell
respons
increas
protect
durat
pa
nanoparticlebas
vaccin
recent
employ
immun
swine
influenza
within
pig
influenza
shakya
et
al
discuss
use
pnipaam
combin
collagen
type
ii
polymer
adjuv
reduc
risk
trigger
autoimmun
respons
sever
studi
describ
enhanc
immunogen
due
adjuv
properti
plga
comparison
nonadjuv
antigen
prime
subunit
vaccin
recommend
review
articl
size
plga
particl
ie
nanoor
microparticl
well
monomer
l
g
ratio
play
crucial
role
modul
immunogen
li
et
al
describ
increas
cytokin
express
ifnc
pertussi
toxoid
vaccin
employ
dualranges
particl
rang
nm
mm
monomer
ratio
anoth
exampl
cruz
et
al
report
increas
tcell
respons
employ
plga
nanoparticl
l
g
encapsul
deliv
protein
vaccin
ligand
tlr
name
shown
improv
immun
respons
cytokin
interleukin
il
encod
plasmid
also
shown
enhanc
immunogen
immun
signal
molecul
like
trif
also
encod
plasmid
success
use
adjuv
along
dna
vaccin
genet
knockdown
gene
like
pdligand
known
counteract
dna
vaccin
use
shrna
sirna
also
shown
effect
adjuv
dna
vaccin
inform
regard
adjuv
specif
use
along
dna
vaccin
pleas
refer
follow
extens
review
articl
li
et
al
saad
f
petrovski
n
section
pro
similar
kinet
approach
nonkinet
method
also
use
achiev
longterm
enhanc
immun
respons
con
adjuv
commonli
use
includ
alum
calcium
salt
caus
sever
inflamm
compat
advantag
certain
antigen
continu
improv
dna
sequenc
technolog
better
understand
key
conserv
sequenc
transcrib
translat
antigen
discov
engin
sequenc
may
use
protect
ie
nucleic
acid
code
mass
produc
dna
recombin
technolog
code
directli
deliv
subsequ
process
display
apc
eventu
seroconvers
patient
transcript
translat
machineri
furthermor
peptid
protein
subunit
thereof
mass
produc
cell
ie
e
coli
yeast
dna
recombin
technolog
manufactur
dna
vaccin
engin
manufactur
dna
vaccin
involv
multidisciplinari
field
molecular
biologybiochemistri
separ
techniqu
materi
scienc
goi
insert
selfrepl
organ
bacteria
yeast
circular
pdna
usual
use
dna
clone
vector
extract
replic
organ
chemic
purifi
pdna
engin
express
bacteria
ie
escherichia
coli
e
coli
yeast
ie
pichia
pastori
amplif
purpos
bioreactor
also
express
mammalian
cell
therapeut
purpos
major
compon
involv
within
engin
dna
plasmid
origin
replic
promot
goi
commonli
antibiot
resist
gene
select
e
colibas
plasmid
product
composit
cultur
media
vari
mineralcontain
media
complex
mixtur
supplement
yeast
extract
replic
bioreactor
bacteria
undergo
lyse
process
alkalin
thermal
treatment
follow
plasmid
purif
precipitationcentrifug
largescal
pdna
product
costeffect
comparison
lav
iv
manufactur
process
possibl
make
technolog
cheaper
long
run
consum
rel
recent
develop
minicircl
episom
dna
miniplasmid
ie
f
ministr
potenti
transport
easili
cellular
barrier
improv
bioavail
sake
breviti
discuss
downstream
process
omit
pleas
refer
follow
articl
downstream
process
inform
date
licens
dna
vaccin
use
human
scientif
commun
high
expect
dna
vaccin
use
follow
reason
abil
control
transcrib
translat
product
therebi
control
abil
antigen
revert
virul
pathogen
form
rel
low
product
cost
dna
vaccin
innat
stabil
dna
vaccin
storag
transport
purpos
potenti
disadvantag
dna
vaccin
could
potenti
trigger
autoimmun
diseas
elicit
antidna
antibodi
product
owe
use
prokaryot
dna
vector
vector
may
contain
unmethyl
cpg
sequenc
may
recogn
pamp
immun
system
ie
result
immun
respons
gilkeson
et
al
associ
prokaryot
doublestrand
dna
dsdna
immun
develop
antidsdna
antibodi
mice
lilic
et
al
describ
induct
antidna
antibodi
administr
subunit
vaccin
hepat
b
viru
hbv
recent
zafrir
et
al
report
hbv
vaccin
induc
autoimmun
syndrom
use
requir
adjuv
hand
studi
suggest
direct
effect
vaccin
trigger
autoimmun
diseas
dna
vaccin
may
caus
indel
mutat
risk
depend
mechan
deliveri
despit
nonvir
gene
deliveri
system
safer
viral
vector
risk
insert
mutagenesi
zero
although
risk
believ
lower
everyday
random
mutat
unfortun
often
nonvir
risk
base
insert
function
fluorescencebas
marker
entir
function
sequenc
must
insert
within
genom
also
region
express
nonvir
risk
insert
mutagenesi
may
higher
current
believ
risk
also
function
sequenc
whether
dna
supercoil
administr
dna
vaccin
expos
patient
foreign
dna
fragment
could
insert
host
chromosom
dna
case
incorpor
exon
insert
mutat
frameshift
mutat
occur
mutat
caus
gene
malfunct
inactiv
ie
tumor
suppressor
gene
insert
foreign
gene
host
genom
could
also
lead
constitu
express
previous
silent
bacterialparasit
gene
insert
insert
may
also
increas
probabl
rearrang
break
guidelin
industri
product
dna
vaccin
publish
fda
recommend
pdna
supercoil
help
prevent
insert
mutagenesi
report
fda
recommend
integr
studi
regardless
deliveri
method
greater
copi
foreign
dna
per
microgram
host
dna
interestingli
minicircl
dna
ministr
dna
report
less
risk
insert
mutagenesi
major
bacteri
dna
ie
unmethyl
cpg
repeat
function
pamp
remov
dna
vaccin
advantag
requir
rigor
temperatur
control
proteinbas
vaccin
requir
howev
stabil
nucleic
acidbas
vaccin
dri
condit
ie
storag
transport
aqueou
condit
highli
depend
stabil
techniqu
crine
et
al
report
stabil
apurin
sequenc
site
remain
undamag
approxim
h
ph
buffer
solut
similar
physiolog
media
karni
et
al
investig
thermal
degrad
rate
pdna
mg
found
complet
degrad
min
aqueou
solut
pdna
incub
aqueou
condit
intact
pdna
could
found
case
dri
pdna
degrad
temperatur
report
low
threshold
incub
pdna
increment
min
found
pdna
start
degrad
complet
degrad
approxim
comparison
degrad
addit
prokaryot
dna
report
thermal
stabl
eukaryot
dna
stabil
nucleic
acid
physiolog
environ
depend
specif
condit
intracellular
tissu
system
level
vivo
environ
variat
ph
exposur
variou
enzym
ie
nucleas
reactiv
oxygen
speci
well
possibl
epigenet
modifi
modifi
host
dna
repair
mechan
develop
deliveri
system
nucleic
acid
eg
polymer
lipid
vector
control
microenviron
nucleic
acid
help
maintain
molecular
stabil
decreas
degrad
rate
present
complex
state
ie
polyplex
lipoplex
versu
free
state
exampl
vivo
halflif
nonion
complex
dna
approxim
min
extracellular
environ
wherea
intracellular
halflif
longer
close
h
despit
advantag
complex
state
term
structur
stabil
dna
excess
complex
success
transcript
effici
plasmid
access
transcript
machineri
evan
et
al
describ
relev
control
main
mechan
dna
degrad
eg
depurinationbelimin
free
radic
oxid
employ
chelat
hydroxyl
radic
scaveng
use
ethanol
edta
ethylenediaminetetraacet
acid
dtpa
diethylenetriaminepentaacet
acid
dnabas
formul
associ
enhanc
remain
dna
amount
approxim
month
incub
peptid
nucleic
acid
pna
uncharg
molecul
demonstr
increas
resist
nucleas
rnase
comparison
endogen
nucleic
acid
benefit
specif
gene
deliveri
dna
vaccin
applic
conjug
pna
cellpenetr
peptid
cpp
enhanc
molecular
stabil
facilit
transfect
addit
highli
stabl
cppconjug
pna
improv
dna
sequenc
recognit
higher
affin
lipid
membran
peptid
backbon
epigenet
modif
affect
molecular
stabil
genet
express
dna
modif
dna
methyl
like
occur
cpgrich
region
methyl
region
may
subsequ
recruit
dna
methylatedbind
protein
histon
deacetylas
hdac
downregul
gene
express
transcript
machineri
access
dna
system
level
elicit
specif
antibodi
subtyp
respons
depend
context
rout
deliveri
method
instanc
vaccin
contain
lactobacillu
vector
influenza
viru
induc
higher
surviv
rate
murin
model
administ
intranas
rout
oral
rout
iga
titer
measur
antihiv
dna
vaccin
titer
found
increas
intranas
rout
comparison
intramuscular
im
rout
dna
vaccin
vaccin
administ
im
rout
induc
greater
titer
wherea
gene
gun
method
elicit
greater
antibodi
respons
cellular
level
transport
highli
charg
macromolecul
dna
across
neg
charg
phospholipid
bilay
membran
subsequ
highli
restrict
nuclear
envelop
challeng
specif
main
barrier
deliveri
pdna
vaccin
follow
stabil
describ
previou
section
cellular
uptak
endolysosom
escap
decomplex
carrier
nuclear
envelop
transloc
cellular
uptak
nonvir
gene
deliveri
carrier
uptaken
clathrinor
caveolaemedi
endocytosi
macropinocytosi
endocyt
pathway
plasmid
intern
within
nucleu
intranuclear
inject
directindirect
nuclear
local
signal
ie
dnatarget
sequenc
encapsul
nuclear
envelop
upon
reform
postmitosi
electropor
ep
caus
transient
pore
plasma
membran
host
cell
increas
uptak
kinet
pdna
electr
field
recent
clinic
trial
dna
vaccin
deliv
imep
use
ichor
medic
system
trigrid
tm
deliveri
system
tdsim
result
demonstr
dna
vaccin
deliv
ep
safe
effect
elicit
strong
immun
respons
anoth
physic
method
develop
deliv
plasmid
epiderm
gene
gun
particlemedi
epiderm
deliveri
pmed
gene
gun
use
preclin
trial
deliv
dna
vaccin
dengu
viru
nonhuman
primat
plasmid
includ
oligonucleotid
sequenc
vaccin
antigen
precipit
onto
mmdiamet
gold
bead
dnaadsorb
gold
bead
deliv
use
gaspressur
gene
gun
needlefre
devic
differ
pmed
term
im
intraderm
inject
use
needl
syring
pmed
enabl
direct
deliveri
vaccin
intracellular
environ
effici
therebi
improv
cellular
uptak
result
higher
immun
respons
substanti
lower
dose
dna
choi
et
al
compar
three
differ
deliveri
method
im
intraderm
epiderm
inocul
use
plasmidco
gold
bead
particlepressur
bombard
ie
gene
gun
intraderm
inject
gene
gun
result
specif
igg
antibodi
respons
iga
despit
induct
igg
respons
gene
gun
intraderm
administr
method
fail
protect
mice
rotaviru
infect
particular
studi
physic
method
includ
physic
punctur
cell
use
microneedl
impalefect
hydrostat
pressur
squeez
cell
microfluid
chamber
addit
ep
sonopor
intranas
deliveri
interest
reader
regard
physic
method
intracellular
deliveri
would
recommend
public
meacham
et
al
subsect
pro
ep
gene
gun
safe
use
deliv
dna
shown
immun
respons
specif
applic
ep
requir
less
dna
without
compromis
efficaci
con
ep
often
invas
limit
vivo
applic
may
lead
cell
death
gene
gun
method
limit
control
insert
site
dna
rel
expens
lipid
cation
aminecontain
polym
often
complex
anion
plasmid
macromolecul
nanos
particl
facilit
cellular
uptak
inhibit
degrad
plasmid
traffick
extracellularli
intracellularli
uncomplex
state
halfliv
plasmid
extracellularli
serum
intracellularli
order
minut
hour
respect
mass
free
polym
carrier
solut
critic
deliveri
effici
typic
administ
manyfold
excess
transfect
occur
owe
need
free
polym
excess
despit
take
advantag
enhanc
permeabl
retent
effect
larger
polyplex
free
polym
abl
suffici
transport
site
interest
reason
nonvir
gene
deliveri
system
often
inject
local
furthermor
mani
research
endeavor
improv
buffer
capac
gener
carrier
excess
toxic
interest
reader
may
refer
follow
review
inform
regard
nonvir
gene
deliveri
barrier
follow
paragraph
discuss
cell
specif
hydrophob
proton
spong
effect
nuclear
uptak
reader
conveni
regard
cell
specif
surfac
modif
employ
enhanc
uptak
structur
carrier
screen
use
highthroughput
method
discov
cell
specif
et
al
demonstr
biodegrad
poli
betaamino
ester
nanoparticl
present
specif
transfect
efficaci
human
brain
tumoriniti
cell
compar
noncancer
cell
similar
result
also
report
previou
work
hepatoma
cell
glioblastoma
cell
exact
mechan
chemic
structurerel
cell
specif
remain
unknown
howev
import
note
cell
specif
nonvir
gene
deliveri
system
due
factor
cellular
divis
rate
cellular
uptak
amount
nanoparticl
media
composit
although
exact
mechan
remain
elus
hypothes
differ
pathway
endocytosi
tune
differ
polym
structur
may
answer
cell
specif
differ
understand
structur
activ
relationship
sar
ongo
endeavor
within
field
enabl
abil
engin
optim
deliveri
system
object
elucid
sar
analysi
interact
cell
membran
amphiphil
materi
demonstr
adsorpt
hydrophob
moieti
ie
lipidbas
system
greater
number
carbon
polym
backbon
side
chain
caus
disrupt
destabil
cell
membran
therebi
facilit
endosom
uptak
therefor
promot
cellular
uptak
often
accomplish
use
polym
lipid
design
increas
interact
nanoparticl
cell
membran
hydrophob
one
main
variabl
vari
optim
nonvir
gene
deliveri
system
intern
endocyt
pathway
pdna
need
effici
escap
endolysosom
degrad
pathway
cytoplasm
avoid
degrad
sever
author
observ
enhanc
endosom
escap
use
polyethyleneimin
pei
conjug
pdna
enhanc
proton
spong
effect
promot
endosom
swell
ruptur
effect
occur
buffer
capac
unproton
amin
group
pei
pei
becom
increasingli
proton
acidif
process
endosom
thu
imbalanc
osmot
pressur
differ
form
across
membran
due
influx
cl
ion
water
molecul
endosom
escap
mechan
involv
fusogen
peptid
exampl
nakas
et
al
suggest
associ
pei
fusogen
peptid
gala
cation
lipidco
exosom
increas
endosom
escap
exosom
use
nucleic
acid
deliveri
hu
et
al
develop
dna
vaccin
malign
melanoma
employ
tatbas
fusogen
peptid
peimannos
nanoparticl
adsorb
onto
microneedl
use
tatbas
fusogen
peptid
result
tcell
activ
enhanc
express
ifnc
nuclear
local
sequenc
also
indirectli
incorpor
pdna
use
dna
target
sequenc
dtss
dt
dna
subsequ
incorpor
pdna
bind
site
nlscontain
protein
presum
dna
separ
complex
karyopherin
abl
help
facilit
nuclear
uptak
plasmid
technolog
deriv
virus
exampl
simian
viru
dt
within
genom
use
mechan
improv
abil
replic
thu
dt
sequenc
aaccagctgtggaatgtgtgtcagttagggt
incorpor
pdna
interest
improv
gene
transfect
similarli
observ
cell
type
subsect
pro
nonvir
deliveri
system
rel
safer
use
viral
counterpart
benefit
costeffect
easier
chemic
modifi
optim
con
nonvir
system
gener
result
temporari
express
also
rel
lower
express
period
express
design
plasmid
entail
select
dna
insert
goi
dna
vector
backbon
plasmid
transform
protocol
depend
speci
host
organ
ie
compet
cell
often
use
transform
e
coli
host
organ
ie
bacteria
e
coli
yeast
p
pastori
rel
recent
technolog
suggest
use
minicircl
dna
increas
therapi
biosafeti
bacteri
dna
remov
parent
plasmid
goi
promot
termin
sequenc
essenti
remain
parent
bacteria
sequenc
absent
greater
extent
lack
cpg
sequenc
result
longer
halfliv
plasmid
howev
specif
applic
encod
cpg
desir
enhanc
immunogen
respons
moreov
studi
demonstr
gene
transfer
use
minicircl
induc
increas
longterm
transgen
express
vivo
vitro
compar
pdna
specif
applic
potenti
improv
immunogen
dna
vaccin
improv
pdna
tge
effici
earli
studi
investig
variou
combin
promotersenhanc
control
gene
express
well
tge
effici
vaccin
sun
et
al
li
et
al
report
use
posttransl
regulatori
element
improv
effici
dna
vaccin
approach
like
benefit
field
codon
optim
adapt
dna
sequenc
speci
augment
express
amino
acid
code
synonym
genet
codon
frequenc
synonym
codon
use
depend
speci
gene
express
optim
util
advantag
inform
codon
usag
specif
organ
plasmid
design
lowfrequ
eukaryot
codon
foreign
dna
backbon
identifi
replac
highfrequ
codon
still
maintain
respect
code
amino
acid
recent
progress
term
enhanc
immunogen
mice
chicken
prime
codonoptim
dna
vaccin
synthet
gene
circuit
provid
tool
accur
control
gene
express
plasmid
sequenc
engin
control
express
ie
technolog
exampl
brophi
voigt
construct
gene
circuit
e
coli
antisens
promot
place
next
termin
studi
function
antisens
promot
regul
group
also
work
design
comput
tool
python
languagebas
dnaplotlib
librari
visual
gene
circuit
outlin
anoth
applic
use
gene
circuit
synthet
biolog
orthogon
polymeras
independ
control
multipl
pathway
cell
use
multipl
activatorchaperon
pair
also
observ
improv
orthogon
gene
circuit
moon
et
al
use
fourinput
gate
control
orthogon
gene
express
multipl
pathway
time
independ
one
anoth
employ
e
coli
dean
et
al
investig
mechan
enabl
control
gene
express
profil
engin
induc
within
genet
circuit
thu
demonstr
potenti
switch
goi
onoff
molecular
control
applic
could
potenti
enabl
regul
immun
respons
term
intens
type
cell
mediatedhumor
futur
vaccin
applic
recent
synthet
biolog
wide
use
genet
engin
applic
conduct
development
function
studi
subsect
pro
plasmid
engin
potenti
method
control
gene
express
current
technolog
gener
limit
nontherapeut
gene
nascent
field
continu
grow
like
great
improv
term
control
express
function
presenc
absenc
key
entiti
synthet
biolog
provid
number
tool
crispr
effici
add
delet
goi
con
extran
mutat
ie
indel
often
occur
technolog
crispr
therebi
lead
sever
side
effect
complex
certain
gene
circuit
lead
unreli
gene
express
safeti
concern
regard
specif
offtarget
effect
need
thoroughli
investig
despit
posit
outlook
dna
vaccin
low
immunogen
henc
requir
immunostimul
adjuv
andor
addit
prime
booster
immunostimul
adjuv
depend
type
may
requir
complex
storag
transport
condit
method
involv
use
cytokin
ie
granulocytemacrophag
colonystimul
factor
gmcsf
proven
use
enhanc
immun
respons
exampl
kalam
et
al
report
andor
produc
safe
immunogen
respons
gag
dna
vaccin
kalam
et
al
also
evalu
posit
impact
ep
deliveri
method
gag
adjuv
plasmid
vector
phase
clinic
trial
studi
also
assess
immunogen
dna
vaccin
contain
chemokineexpress
sequenc
immun
cpg
oligodeoxynucleotid
odn
anoth
common
genet
adjuv
use
dna
vaccin
preclin
studi
demonstr
cpg
odn
activ
b
cell
plasmacytoid
dendrit
cell
support
induct
strong
respons
addit
engin
ratio
cpg
motif
dna
vaccin
improv
immunogen
administ
addit
synthet
cpg
odn
coadminist
second
plasmid
clone
cpg
motif
investig
kojima
et
al
deliv
cpgencod
plasmid
day
day
hiv
dna
vaccin
deliv
well
time
result
show
signific
boost
hivspecif
igg
cytotox
lymphocyt
activ
obtain
cpg
plasmid
administ
either
day
hiv
dna
vaccin
consecut
immun
use
primeboost
strategi
also
appli
mani
clinic
trial
overcom
poor
immunogen
dna
vaccin
immun
involv
prime
dna
vaccin
follow
boost
recombin
antigen
protein
exampl
dale
et
al
investig
use
pdna
recombin
fowlpox
viru
rfpv
vaccin
potenti
vaccin
candid
group
demonstr
primeboost
vaccin
system
induc
stronger
antigenspecif
tcell
respons
larg
immedi
tcell
immun
respons
observ
administ
rfpv
boost
macaqu
day
prime
dna
vaccin
howev
similar
boost
immun
may
obtain
reboost
second
dose
recombin
protein
vaccin
suggest
dose
interv
dose
multipl
boost
vaccin
need
evalu
accord
dna
vaccin
databas
dnavaxdb
articl
relat
dna
vaccin
includ
year
index
pubm
googl
scholar
howev
extent
knowledg
yet
licens
dna
vaccin
use
human
us
europ
japan
genebas
formul
requir
greater
safeti
evalu
convent
vaccin
eg
nucleic
acid
integr
host
chromosom
genom
timelin
approv
dna
vaccin
human
rel
lengthi
tabl
recent
licens
protein
dna
vaccin
therapi
data
extract
relat
infecti
diseas
vaccin
target
tabl
although
noninfecti
vaccin
main
focu
review
two
vaccin
includ
tabl
provid
wholist
pictur
current
progress
dna
anim
vaccin
date
clinic
trial
earli
phase
phase
iv
search
term
dna
vaccin
accord
clinicaltrialgov
us
respons
clinic
trial
studi
suspend
termin
withdrawn
unknown
statu
exclud
number
detail
patent
andor
sponsor
dna
vaccin
technolog
summar
tabl
major
trial
select
trial
investig
prophylact
vaccin
infecti
diseas
ie
hiv
influenza
hepat
b
infect
detail
analysi
clinic
trial
genebas
prophylact
vaccin
includ
viru
vaccin
report
nakayama
et
al
date
clinic
trial
demonstr
signific
evid
indic
dna
insert
mutagenesi
chromosom
host
immunolog
toler
term
develop
antidna
antibodi
howev
transfect
effici
dna
plasmid
gener
poor
result
insuffici
induct
immun
respons
possibl
one
greatest
challeng
current
clinic
trial
result
trial
util
hybrid
formul
ie
cpg
andor
higher
dna
dose
greater
express
level
immunogen
number
current
clinic
trial
hiv
infect
exampl
endeavor
vaccin
current
phase
ii
constitut
two
compon
dna
vaccin
use
prime
person
immun
respons
recombin
mva
modifi
vaccinia
ankara
attenu
vaccin
use
boost
prime
respons
studi
conduct
hivinfect
particip
current
undergo
antiretrovir
treatment
demonstr
capabl
elicit
antibodi
cell
respons
heterolog
challeng
hand
pennvax
dna
vaccin
develop
inovio
pharmaceut
current
phase
util
primeboost
strategi
similar
combin
viral
vector
vaccin
furthermor
inovio
demonstr
immun
respons
enhanc
pennvax
deliv
vivo
intraderm
ep
compar
syring
inject
result
reveal
modif
dna
vaccin
formul
combinatori
deliveri
approach
improv
potenc
efficaci
dna
vaccin
human
clinic
trial
summari
larg
number
secondgener
vaccin
licens
releas
market
dna
vaccin
also
approv
sale
anim
health
applic
summar
tabl
report
provid
evid
potenti
growth
market
new
vaccin
technolog
regard
feasibl
current
trial
dna
vaccin
advanc
plasmid
formul
deliveri
approach
necessari
dna
vaccin
platform
realiz
within
human
optim
vaccin
schedul
gener
limit
investig
time
vari
month
optim
vaccin
schedul
smaller
step
time
like
result
enhanc
seroconvers
protect
term
engin
kinet
vaccin
autoboost
technolog
practic
receiv
dose
short
time
scale
increasingli
reason
new
technolog
seal
serious
need
like
highli
impact
potenti
complic
junction
seal
must
mitig
extent
possibl
howev
remov
need
seal
would
advantag
highli
challeng
endeavor
would
like
worthwhil
ie
direct
inject
system
microfluidicbas
technolog
enhanc
abil
stabil
cargo
within
challeng
depot
environ
optim
cater
given
antigen
possibl
within
depot
vaccin
system
term
excipi
cryoprotect
content
well
ratio
excipi
antigen
howev
multipl
antigen
type
deliv
vaccin
depot
highli
challeng
cater
multipl
antigen
type
optim
fashion
within
singl
depot
endeavor
deliv
vaccin
depot
environ
optim
cater
specif
antigen
within
given
inject
vaccin
system
would
also
benefici
challeng
engin
standpoint
date
although
clinic
translat
genebas
system
limit
us
recent
approv
two
gene
therapi
genemodul
technolog
receiv
approv
obtain
k
clearanc
increasingli
common
field
dna
vaccin
although
promis
suffer
limit
owe
inabl
suffici
immunogen
techniqu
engin
dnabas
system
primeboost
method
well
incorpor
adjuv
transcribedtransl
codeliv
continu
improv
immunogen
attain
protect
seroconvers
current
safeti
assess
gene
deliveri
system
undergo
approv
process
arduou
determin
risk
insert
mutagenesi
although
gene
sequenc
becom
increasingli
cheaper
year
conduct
qrtpcr
qpcr
time
consum
requir
rel
sophist
instrument
comparison
fluorescencebas
assay
endeavor
properli
assess
insert
mutagenesi
risk
genemodul
technolog
would
probabl
highli
use
assay
fluorescencebas
suffici
reliabl
develop
vaccin
improv
function
interdisciplinaryfocus
research
great
util
light
research
discuss
herein
vaccin
realm
experienc
great
improv
follow
area
come
year
optim
vaccin
schedul
durat
protect
nonkinet
approach
enhanc
antigen
stabil
improv
immunogen
dna
vaccin
manufactur
engin
vaccin
gener
abil
control
gene
circuit
genemodul
technolog
